Keel Point’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $469K | Sell |
7,738
-2,420
| -24% | -$141K | 0.03% | 275 |
|
|
2025
Q4 | $548K | Buy |
10,158
+2,104
| +26% | +$101K | 0.03% | 278 |
|
|
2025
Q3 | $363K | Buy |
8,054
+728
| +10% | +$34K | 0.02% | 372 |
|
|
2025
Q2 | $339K | Buy |
7,326
+526
| +8% | +$25.8K | 0.02% | 376 |
|
|
2025
Q1 | $415K | Buy |
6,800
+1,152
| +20% | +$67.1K | 0.03% | 289 |
|
|
2024
Q4 | $319K | Buy |
5,648
+642
| +13% | +$35.9K | 0.03% | 318 |
|
|
2024
Q3 | $259K | Buy |
5,006
+104
| +2% | +$4.88K | 0.02% | 363 |
|
|
2024
Q2 | $240K | Buy |
4,902
+575
| +13% | +$25.7K | 0.02% | 372 |
|
|
2024
Q1 | $235K | Buy |
+4,327
| New | +$220K | 0.02% | 335 |
|
|
2023
Q4 | – | Sell |
-3,972
| Closed | -$231K | – | 353 |
|
|
2023
Q3 | $231K | Sell |
3,972
-347
| -8% | -$21.3K | 0.03% | 275 |
|
|
2023
Q2 | $276K | Buy |
4,319
+851
| +25% | +$57.1K | 0.04% | 258 |
|
|
2023
Q1 | $240K | Sell |
3,468
-104
| -3% | -$7.33K | 0.03% | 263 |
|
|
2022
Q4 | $257K | Buy |
3,572
+743
| +26% | +$56K | 0.04% | 244 |
|
|
2022
Q3 | $201K | Buy |
2,829
+23
| +0.8% | +$1.67K | 0.03% | 238 |
|
|
2022
Q2 | $210K | Sell |
2,806
-263
| -9% | -$20K | 0.03% | 239 |
|
|
2022
Q1 | $224K | Buy |
+3,069
| New | +$206K | 0.03% | 239 |
|
|
2019
Q1 | – | Sell |
-6,355
| Closed | -$330K | – | 197 |
|
|
2018
Q4 | $330K | Sell |
6,355
-450
| -7% | -$24.2K | 0.04% | 149 |
|
|
2018
Q3 | $422K | Buy |
6,805
+480
| +8% | +$28.5K | 0.05% | 116 |
|
|
2018
Q2 | $350K | Hold |
6,325
| – | – | 0.05% | 120 |
|
|
2018
Q1 | $400K | Hold |
6,325
| – | – | 0.05% | 106 |
|
|
2017
Q4 | $388K | Hold |
6,325
| – | – | 0.05% | 114 |
|
|
2017
Q3 | $403K | Hold |
6,325
| – | – | 0.06% | 113 |
|
|
2017
Q2 | $352K | Buy |
6,325
+39
| +0.6% | +$2.12K | 0.07% | 111 |
|
|
2017
Q1 | $342K | Buy |
6,286
+18
| +0.3% | +$987 | 0.07% | 113 |
|
|
2016
Q4 | $366K | Sell |
6,268
-1,697
| -21% | -$92.8K | 0.08% | 103 |
|
|
2016
Q3 | $429K | Hold |
7,965
| – | – | 0.16% | 87 |
|
|
2016
Q2 | $586K | Hold |
7,965
| – | – | 0.25% | 71 |
|
|
2016
Q1 | $509K | Sell |
7,965
-346
| -4% | -$21.8K | 0.26% | 67 |
|
|
2015
Q4 | $572K | Sell |
8,311
-133
| -2% | -$8.79K | 0.31% | 65 |
|
|
2015
Q3 | $500K | Sell |
8,444
-291
| -3% | -$18.5K | 0.28% | 55 |
|
|
2015
Q2 | $584K | Buy |
8,735
+384
| +5% | +$25.3K | 0.28% | 54 |
|
|
2015
Q1 | $539K | Buy |
+8,351
| New | +$523K | 0.27% | 57 |
|
Other funds holding BMY
VCM
VPM
Keel Point's BMY Position: Q1 2026 in Review
Keel Point reduced its Bristol-Myers Squibb (BMY) stake by 24% in Q1 2026, selling an estimated $141K and leaving 7,738 shares worth $469K. The position accounts for 0.03% of the portfolio, ranked #275.
Keel Point first reported a position in BMY in Q1 2015 and has held it in 32 quarters since. The position peaked at $586K in Q2 2016. 2,518 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Keel Point held 7,738 shares of Bristol-Myers Squibb worth $469K as of Q1 2026.
- Keel Point sold 2,420 Bristol-Myers Squibb shares in Q1 2026, an estimated $141K.
- Bristol-Myers Squibb made up 0.03% of Keel Point's portfolio in Q1 2026, its #275 holding.
- Keel Point first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 32 quarters since.
- Keel Point's Bristol-Myers Squibb position peaked at $586K in Q2 2016.
- 2,518 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Keel Point's 13F filing for Q1 2026, filed 1 Jun 2026.